Weekly Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings

May 17, 2018 - By Tamara Reed

Theravance Biopharma, Inc. (NASDAQ:TBPH) Corporate Logo
During Q4 2017 the big money sentiment decreased to 1.31. That’s change of 0.01, from 2017Q3’s 1.32. 7 investors sold all, 22 reduced holdings as Theravance Biopharma, Inc. ratio dropped. 26 rose positions while 12 funds bought positions. Funds hold 35.06 million shares thus 1.11% less from 2017Q3’s 35.46 million shares.
Teacher Retirement Sys Of Texas invested in 14,931 shs or 0% of the stock. Jpmorgan Chase And holds 10,181 shs or 0% of its capital. Landscape Capital Mngmt Ltd Company has 0.03% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 11,216 shs. Amundi Pioneer Asset Management owns 1,500 shs. Invesco reported 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Voya Investment Mngmt Limited Liability Corporation stated it has 18,950 shs or 0% of all its holdings. Nj State Employees Deferred Compensation Plan has invested 0.16% of its capital in Theravance Biopharma, Inc. (NASDAQ:TBPH). Manufacturers Life Ins The, a Ontario – Canada-based fund reported 30,964 shs. Panagora Asset Mgmt stated it has 3,111 shs or 0% of all its holdings. Geode Management Ltd Liability Com holds 373,476 shs or 0% of its capital. Sei Invs reported 8 shs. Baupost Grp Incorporated Ltd Company Ma holds 2.57% or 9.31 million shs. Moreover, State Street Corporation has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 883,096 shs. Citigroup Incorporated has 358 shs for 0% of their capital. Balyasny Asset Mngmt Ltd Liability Corp has 88,692 shs for 0.01% of their capital.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

In total 3 analysts cover Theravance Biopharma (NASDAQ:TBPH). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:TBPH) has 100% bullish analysts. 4 are the (NASDAQ:TBPH)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. The company rating was maintained by Cantor Fitzgerald on Tuesday, February 27. On Tuesday, May 8 the company was maintained by Cantor Fitzgerald. On Thursday, February 8 Leerink Swann maintained the shares of TBPH in report with “Outperform” rating. On Thursday, March 29 the stock has “Buy” rating by Piper Jaffray. Listed here are Theravance Biopharma, Inc. (NASDAQ:TBPH) PTs and latest ratings.

08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0000 Maintain
29/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $45.0000 Initiate
27/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0 Maintain
08/02/2018 Broker: Leerink Swann Rating: Outperform Old Target: $45 New Target: $48 Maintain

The stock decreased 1.30% or $0.32 during the last trading session, hitting $24.35.Currently Theravance Biopharma, Inc. is downtrending after 26.76% change in last May 17, 2017. TBPH has also 175,081 shares volume. TBPH underperformed the S&P500 by 38.31%.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics.The company has $1.34 billion market cap. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.Currently it has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

More recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were released by Streetinsider.com, Seekingalpha.com and Prnewswire.com. The first one has “Theravance Biopharma (TBPH) Announces Approval of Expanded Indication in US for Once-Daily Trelegy Ellipta for …” as a title and was released on April 25, 2018. The next is “Theravance Biopharma’s (TBPH) CEO Rick Winningham on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. And last was released on April 20, 2018, called “Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical …”.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.